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Abstract 
Regenerative medicine is a diverse and rapidly evolving field, employing core expertise from 
biologists, engineers, and clinicians. Recently the field has made significant progress 
towards regenerating or replacing tissues lost to age, disease or injury. Current strategies 
include transplantation of adult or pluripotent stem cells to replace tissue or support tissue 
healing. Promising approaches for the future of regenerative medicine include stimulating 
endogenous stem cells for in situ repair, transplantation of organoids to repair minor tissue 
injury, and the use of interspecies chimerism to produce functional metabolic organs for 
transplantation. In our review we focus on these emerging strategies, paying particular 
attention to their current and prospective translational impacts and challenges.
Introduction
Transplantation of adult stem cells is a well-established technology to treat disease, with 
hematopoietic stem cell transplantation in wide spread clinical use for over 50 years. 
Nevertheless, this technology continues to find new clinical applications. For example, recent 
results from an international clinical trial showed that high-dose immunosuppressive therapy 
and subsequent autologous hematopoietic stem cell (HSC) transplantation is effective in 
inducing long-term sustained remissions of active relapsing-remitting multiple sclerosis 
[NCT00273364] [1]. In this trial only 6% of patients treated with HSCs relapsed, compared to 
60% in the untreated control group. Similarly, autologous cultured epidermis transplantation 
is a long-established approach. Notable progress has recently been made in the treatment of 
2skin blistering disorders by gene correction of epidermal cells, followed by their expansion in 
culture and subsequent transplantation [2]**. In a recent world first, this graft technique was 
used to completely replace the skin of a child with epidermolysis bullosa (EB). 
Allogeneic MSC transplantation has also been widely used in patients to treat a range of 
conditions [3]. However, evidence of efficacy has been lacking in many cases. Recent 
studies of patients with graft-versus-host disease (GvHD) suggest that successful treatment 
is determined by the state of the patient’s immune system rather than by the state of the 
infused MSC. Galleu et al. (2017) found that patients who had high cytotoxic T cell activity 
against MSCs responded to MSC infusion, whereas those with low activity did not [4]. After 
infusion, host phagocytes engulfed apoptotic MSCs and produced indoleamine 2,3-
dioxygenase, which was necessary for the immunosuppressive effect of MSCs. This 
suggests that patients should be stratified for MSC treatment according to their cytotoxic T 
cell activity, or, alternatively that patients could be treated with apoptotic MSCs. 
While adult stem cell therapies continue to find new and exciting clinical applications, adult 
stem cells can only give rise to a limited number of cell types and can be hard to scale. This 
has driven the development of many next-generation regenerative strategies. The new 
approaches include methods to promote endogenous tissue repair, through the use of 
pharmacological bio-scaffolds [5], in vivo cell reprogramming [6], and senolytics [7], methods 
to produce novel autologous cell therapies using induced pluripotent stem cells (iPSCs) [8]*, 
and techniques aimed at engineering functional human tissues and organs through in vitro 
tissue engineering [9]** and interspecies chimerism [10]**. In this review we will focus on 
these emerging strategies in the field of regenerative medicine and discuss the technical and 
translational challenges they pose. 
In situ regeneration
An attractive strategy for regenerative medicine is to target endogenous repair mechanisms 
in resident cell populations. A promising approach for this is through the recruitment of 
tissue-resident stem populations following trauma. Implanted biological scaffolds (bio-
scaffolds) provide structural support for functional tissue regrowth and facilitate localised 
delivery of pro-regenerative agents [11]. A recent advance has been the use of a clinically-
approved degradable collagen sponge seeded with a GSK3 inhibitor to promote 
mesenchymal stem cell (MSC)-based dentine regeneration in a rodent model. While this 
represents a new approach to tooth repair [5], significant concerns are the off-target effects 
of broad stimulation of pro-regenerative pathways and the possibility that continued 
3activation of somatic stem cells might lead to their depletion and loss of regenerative 
capacity.
An alternative in situ approach for regenerative medicine is reprogramming of terminally 
differentiated cells. One current strategy for in vivo reprogramming involves enforcing 
expression of key regulatory transcription factors (TFs) to convert cells to an alternative 
mature state [6]. This strategy can be employed to generate functional cells to replace those 
lost through disease. Insulin positive pancreatic β-like cells have been successfully 
generated in mice from pancreatic exocrine [12], hepatic [13] and gastrointestinal [14] cells 
following virus-mediated delivery or transgenic expression of a combination of pancreatic 
TFs. This partially alleviates hyperglycaemia in diabetic murine models. Alternatively 
pathological cells can be reprogrammed to ameliorate disease, as with the conversion of 
myofibroblasts to hepatic-like cells in induced murine models of liver damage, through 
adenovirus-mediated induction of a combination of hepatic TFs [15,16]. Nevertheless, the 
efficiency of reprogramming cells in vivo is generally low, which may contribute to the limited 
translation of this approach into the clinic. 
Cellular senescence has recently been characterised to promote in vivo reprogramming. 
Senescent cells have permanently withdrawn from the cell cycle and adopt a senescence-
associated secretory phenotype (SASP) that is characterised by the secretion of a range of 
factors, including IL-6 [17]. Treatment of animals with an anti-IL-6 antibody decreases the 
expression of SASP components and significantly reduces reprogramming in mice using the 
Yamanaka factors Oct4, Sox2, Klf4, and c-Myc (OSKM) [18]*. Conversely, transient 
treatment with recombinant IL-6 increases the number of in vivo reprogrammed cells [18]*. In 
contrast, chronic exposure to SASP components is thought to hinder native regeneration in 
multiple tissues [19]. Pharmacological agents which induce apoptosis in senescent cells 
(senolytics) [7] have been shown to positively influence regenerative capacity in several 
models of age-related disease [20–23]. Naturally aged mice treated with senolytics have 
significantly improved hematopoietic stem cell serial repopulation capacity [20], reduction in 
age-associated myeloid skewing [20] and increased renal function and hair follicle density 
[22]. A proposed model to explain the dual role of senescence in plasticity and regeneration 
is the length of exposure to SASP components, whereby short-term exposure is beneficial, 
but prolonged exposure induces further senescence and a regenerative block [24].
Pluripotent stem cell therapies
4Pluripotent stem cells (PSCs) have the capacity for unlimited self-renewal and the ability to 
differentiate into any cell type. This makes them an attractive alternative to lineage-restricted 
adult stem cells, and particularly amenable to cell replacement therapies involving difficult to 
obtain cell types. Delivery of PSCs or their differentiated progeny into damaged tissues with 
low regenerative capacity may aid tissue repair by replacing lost cells or providing trophic 
support [25].
Due to its accessibility, immunoprivileged nature and high clinical need, the eye is an 
attractive target for cell replacement therapies. The first evidence of long-term safety, graft 
survival and efficacy of transplanted pluripotent stem cells was demonstrated in 2016: a 
suspension of retinal pigmented epithelial (RPE) cells derived from embryonic stem cells 
(ESC-RPE) was injected into the eyes of nine patients with age-related macular 
degeneration (AMD), resulting in sustained visual improvement in approximately half of 
treated individuals up to 37 months [26]. Culture of RPE on biological scaffolds, and 
transplantation as a more physiologically-representative ‘sheet’, shows optimised 
differentiation, polarisation, engraftment, viability and efficacy when compared to cell 
suspensions [27]. In a world-first induced pluripotent stem cell (iPSC) trial, integration-free 
autologous iPSC-RPE sheets were grown on collagen and successfully engrafted into one 
patient with AMD (UMIN000011929). However, visual improvements have not been reported 
after one year [8]*. Recently, ESC-RPE sheets have been manufactured on decellularized 
amniotic membrane[28] and a synthetic vitronectin-coated polyester membrane [29]**. 
Successful transplantation of this ‘synthetic’ ESC-RPE patch in two patients has resulted in 
significant improvements in visual acuity 12 months after surgery with only local 
immunosuppression (NCT01691261) [29]**. 
Recently, integration-free iPSC-derived neural stem/progenitor cells (iNSPCs) generated 
from patient urine samples were shown to successfully engraft and differentiate in a mouse 
model of spinal cord injury (SCI) [30]. Transplantation of iPSC-derived dopaminergic 
neurons (iDAs) was demonstrated to ameliorate locomotor symptoms of Parkinson’s disease 
(PD) in rodents [31,32] and primates [33], and clinical trials are expected to begin soon [34]. 
Indeed, a clinical trial involving NSPCs derived from chemically-activated ‘parthenogenetic’ 
embryos to treat PD is currently underway (NCT02452723), following improved behavioural 
recovery after intracerebral transplant in Parkinsonian monkeys [35]*.
Epidurally transplanted iNSPCs have been used to enhance functional recovery after stroke 
in rats by paracrine activation of Notch1 signalling in endogenous progenitors [36]. A 
permissive microenvironment promoting engraftment, survival and maturation can also be 
achieved by exogenous addition of growth factors [37,38] or genetic engineering of 
5transplanted cells to overexpress neurotrophic factors such as SDF-1α [39], Nurr1 and 
Foxa2 [40].
In conclusion, sophisticated methods for PSC derivation and transplantation have advanced 
basic research, but extensive preclinical analysis of all cell therapies with respect to cell 
origin (embryo, foetus, iPSC), tumorigenicity, potency, administration strategy (suspension, 
monolayer, encapsulation [41]) and mode of action must be performed to enable safe 
integration into the clinic [42]*. Clinical trials must begin to recruit more participants to enable 
robust statistical analysis of each cell therapy. Rapid delivery of thoroughly regulated 
personalised therapies within a critical treatment window may not be feasible for many acute 
diseases, unless banks of ESCs or iPSC are developed. Finally, these therapies are often 
not suitable for polygenic or systemic diseases affecting more complex structures.
3D-cultured organoids
Advances in 3D tissue engineering allow for the generation of ‘miniature organs’ (organoids) 
in vitro [43]. Organoids are self-renewing, self-organising 3D cell clusters that contain organ-
specific cell types and mimic organ function and morphology. While organoids can be 
obtained from multicellular tissue samples, such as intestinal crypts [44], they can also be 
grown and expanded from pluripotent stem cells [43]. Although organoids have been 
successfully cultured to simulate organs such as kidney [45], liver [46], small intestine [43] 
and brain [47]*, until recently they have mostly found applications in developmental biology 
research and disease modelling [48]. 
Organoids are commonly cultured in Matrigel, an undefined tumour-derived extracellular 
matrix (ECM), and this hampers their potential use in the clinic due to risks of immunogen 
and pathogen transfer [49]*. To circumvent this issue, Cruz-Acuna et al. substituted Matrigel 
with a fully defined synthetic hydrogel based on a four-armed, maleimide-terminated 
poly(ethylene glycol) (PEG-4MAL) macromer as a matrix for organoid culture [9]**. Human 
intestinal organoids (HIOs) grown in this matrix exhibited morphology and proliferation 
similar to those of HIOs grown in Matrigel. Moreover, when implanted under the kidney 
capsule of immunocompromised NSG mice, HIOs generated in PEG-4MAL successfully 
developed into mature intestinal tissue, exhibiting markers for intestinal epithelial, 
enteroendocrine, goblet and tuft cells, all found in the normal intestine. To further prove the 
feasibility of using HIOs clinically, Cruz-Acuna et al. injected HIOs at the site of mechanically 
induced mucosal wounds in the mouse colon with PEG-4MAL hydrogel as an injection 
vehicle, resulting in organoid engraftment and improved wound repair compared to controls 
6[9]** (Figure 2). This study shows that not only do intestinal organoids have clinical potential 
in the field of tissue repair, but also that fully defined, synthetic hydrogels can be used both 
as a culture matrix and as an injection vehicle for organoids, overcoming the obstacle 
presented by Matrigel-based organoid culture. 
While attempts are being made to improve organoid technology so that it can be employed 
in the regeneration of other tissues, such as liver [46] and kidney [45], the long culture time 
and the lack of organ-specific macro-architecture and vascularisation limit the clinical 
applications of organoids to the repair of small defects, or of defects in organs with a 
relatively simple structure, such as the intestine. Therefore, a more ambitious tissue 
engineering approach may be necessary for the treatment of large defects in organs with 
complex architectures.
Interspecies chimeric organs
An innovative approach to treat severe tissue defects while also addressing the organ 
shortage crisis is the generation of whole organs via interspecies chimeras. Host animals 
can potentially be engineered to grow humanised organs suitable for transplantation, in a 
process called interspecies chimerism. Recent studies in rodents [10]** have demonstrated 
how, while technically feasible, this strategy would be clinically challenging. 
Through genetic manipulation, it is possible to create a developmental niche in a host animal 
that can be populated by PSCs from a donor animal, generating a chimeric organ consisting 
mostly of donor cells. Cells are commonly injected at the blastocyst stage in an approach 
known as blastocyst complementation [50]. A recent proof-of-concept study by Yamaguchi et 
al. [10]** has demonstrated successful generation of mouse pancreata in Pdx-1-deficient 
rats using this technique. Islets from these rat chimeras were transplanted into mice with 
streptozotocin-induced diabetes, normalising blood glucose levels in the absence of 
immunosuppression (Figure 3). 
Rat-mouse chimeric nephrons have also been generated following removal of nephron 
progenitor cells (NPCs) from the post-implantation rat foetus with a time-specific cell 
elimination strategy, creating a niche for injected mouse NPCs [51]. This establishes the 
possibility of generating organs with more complex developmental controls than the 
pancreas but is still far removed from whole kidney organogenesis. 
The success of rat-mouse chimeras [52,53] has provided a foundation for generating human 
organs in a host species. Pigs serve as a good candidate animal due to their similar organ 
7size, physiology and anatomy. However, fluorescently labelled human PSCs (hPSC) injected 
into pig blastocysts show inefficient contribution to chimera formation [54]. An intermediate 
hPSC shows improved contribution and differentiation into several cell types post-
implantation but contribution from all hPSCs is still much lower than that observed in rat-
mouse chimeras. This may be due to the larger degree of evolutionary distance between 
humans and pigs. Future research might consider the use of non-human primates which are 
evolutionarily closer to humans. 
Engraftment and survival of donor cells in chimeras can be improved by matching the 
developmental timing of cells to the host. Despite the large evolutionary distance, Cohen et 
al. [55] were able to generate mouse-human neural crest chimeras by injecting human 
neural crest cells (NCCs) into post-gastrulation mouse embryos at the stage when NCCs 
delaminate from the neuroepithelium. Donor cells survived, migrated along normal migration 
routes and contributed to functional pigment cells. Inhibiting apoptosis can improve 
integration of cells in later stages of development [56]. This may help prevent donor cells 
from contributing to other parts of the host, addressing a serious ethical concern [57]. 
Despite exciting progress, we are still a long way from generating human organs for 
transplantation, but chimeric animals may soon enable the study of human organ generation 
in vivo.
Concluding remarks
The field of regenerative medicine is advancing at an unprecedented rate. Adult stem cell 
transplantation, whilst well established in the clinic for some diseases, is not a viable solution 
for many other more localised disorders that may require specialised cell replacement. 
Pluripotent stem cells that can give rise to theoretically any cell type offer a promising 
alternative transplantation approach. Streamlining the generation of clinical-grade cell lines 
and reducing the tumourigenic risk associated with stem cell therapy are priorities for 
progression to wide-spread clinical use. Novel approaches targeting cell populations in situ 
are an exciting area of research, which could circumvent immunogenic risk associated with 
exogenous tissue transplantation. Considerations regarding target specific effects and long-
term depletion of resident stem cell populations would need to be addressed for the 
advancement of this approach. Finally, more ambitious but less clinically advanced 
approaches aim to generate human organs in vitro or through interspecies chimerism. The 
ability to culture organs would have a considerable impact, alleviating the need for donor 
tissue. Key challenges include generating in vitro organoids with sufficiently complex 
vascularised networks and 3D architectures, alongside niche optimisation to facilitate 
8effective human interspecies chimerism. Future developments in the field of regenerative 
medicine will not only translate current strategies to the clinic, but also drive novel and 
complementary strategies to treat a broad range of diseases.
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Figure legends
Figure 1. Current strategies in regenerative medicine. Somatic stem cells can be 
targeted in situ, through the application of bioscaffolds seeded with pro-regenerative agents, 
to activate endogenous repair mechanisms [5]. Alternatively, tissue resident cells can be 
reprogrammed from a pathophysiological state [15,16] or to an alternative functional state 
[14,58] to alleviate disease. Adult, embryonic or induced pluripotent stem cells can also be 
transplanted to enhance regeneration. This may include ex vivo expansion and gene editing 
to correct pathogenic mutations. Transplantation of organoids shows promise as a strategy 
to improve regeneration [9]**. Finally, the generation of human-animal chimeras could 
facilitate the culture of entire human organs. Bioscaffolds, biological scaffolds. 
Figure 2. Organoid culture and transplant for intestinal tissue regeneration. Human 
pluripotent stem cells can be induced to generate intestinal organoids that can then be 
expanded in PEG-4MAL hydrogel. The organoids can be delivered to the injury site using a 
hydrogel-based injection vehicle, resulting in ameliorated wound repair [9]**.
Figure 3. Schematic representation of blastocyst complementation to generate a 
functional mouse pancreas in a rat. Figure adapted from Yamaguchi et al. 2017 [10]**.
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